suzetrigine

Suzetrigine is a first-in-class non-opioid analgesic approved for the treatment of moderate to severe acute pain in adults. It is a small molecule that acts as a highly selective blocker of the NaV1.8 voltage-gated sodium channel found in peripheral sensory neurons. By inhibiting NaV1.8 (Sodium channel protein type 1 subunit alpha)—specifically by binding to its second voltage sensing domain (VSD2) and stabilizing the closed state—suzetrigine disrupts pain signal transmission from peripheral nerves to the spinal cord and brain without affecting central nervous system function or causing addictive potential. Clinical trials have shown that suzetrigine provides pain relief comparable to opioid combinations but without risks such as addiction or sedation. The drug was developed by Vertex Pharmaceuticals and is marketed under the brand name Journavx[1][2][5][6][7].

Brand names

Journavx

Other names

4-[[[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide